European, American and Japanese regulators are to work more closely together to engender the development of new antibiotics.
The move, like the recent updated guidance from the World Health Organization on the use of antibiotics, is aimed at curbing the growing problem of antimicrobial resistance.
Regulators in the three jurisdictions want to align data requirements and agree on areas of convergence.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze